Applied Biosystems to Invest in VisiGen Biotechnologies
News Jan 05, 2006
VisiGen's technological approach to DNA sequencing is based on the ability to analyse a single molecule of DNA in real time, which has the potential to reduce the cost of sequencing and improve throughput compared to existing commercially available technologies.
Their solution could provide a quantum leap in the scope and scale of research aimed at uncovering the genetic basis of common diseases such as cancer, heart disease and diabetes.
"Applied Biosystems continues to extensively evaluate potential next-generation sequencing technologies," explained Catherine M. Burzik, President of Applied Biosystems.
"We believe that the quality of VisiGen's science and the progress towards the development of single-molecule sequencing technology is quite impressive."
Dr Susan Harding, President and CEO of VisiGen, continued, "VisiGen's approach of monitoring parallel arrays of single molecules could allow large-scale sequencing projects in the areas of cancer and other diseases and could make sequencing-based targeted medicine a reality."
"This investment by Applied Biosystems, and its expertise in DNA sequencing, makes it an ideal partner for us as we work towards commercialisation."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE